251 results on '"Taki, Masashi"'
Search Results
2. Hemostatic balance between pro‐ and anticoagulant is maintained during glucocorticoid treatment
3. Hemostatic balance between pro‐ and anticoagulant is maintained during glucocorticoid treatment.
4. HTRS2023.P2.11 Personalized prophylaxis with simoctocog alfa in adult Japanese previously treated patients with severe hemophilia A
5. Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan
6. Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan
7. Perioperative safety and hemostatic efficacy of Advate® in patients with hemophilia A in a postmarketing surveillance in Japan
8. Plasma‐derived factor VIIa and factor X mixture agent (MC710) prophylaxis in haemophilia B patients with inhibitors
9. The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs
10. AOZORA Study: Interim Analysis of Joint Health in Children with Hemophilia A, without FVIII Inhibitors, 3 Years after Initiating Emicizumab
11. Efficacy and Safety of Personalized Prophylaxis with Simoctocog Alfa in Adult Japanese Previously Treated Patients with Severe Hemophilia a
12. Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations
13. Pediatric thromboembolism: a national survey in Japan
14. Estimation of the Number of Sustained Viral Responders by Interferon Therapy Using Random Numbers with a Logistic Model
15. First case report of hemophilia B Leyden in Japan
16. A cohort study of the usefulness of primary prophylaxis in patients with severe haemophilia A
17. Clinical and pathophysiological delineation of musculocontractural Ehlers—Danlos syndrome caused by dermatan sulfate epimerase deficiency (mcEDS‐ DSE ): A detailed and comprehensive glycobiological and pathological investigation in a novel patient
18. AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab – protocol for a multicentre, open-label, phase IV clinical study
19. Plasma‐derived factor VIIa and factor X mixture agent (MC710) prophylaxis in haemophilia B patients with inhibitors.
20. The International Immune Tolerance Induction Study and its follow-up study on Japanese hemophilia A patients with inhibitors
21. Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan
22. Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial
23. Correction to: Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations
24. Usefulness of Cross-Mixing Test for Immune Thrombocytopenia in a Pediatric Patient with Coagulation Abnormalities
25. Safety and effectiveness of albutrepenonacog alfa in Japanese patients with hemophilia B: Interim report of a post-marketing surveillance study
26. Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
27. Clinical conditions and risk factors for inhibitor‐development in patients with haemophilia: A decade‐long prospective cohort study in Japan, J‐HIS2 (Japan Hemophilia Inhibitor Study 2).
28. The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals
29. Current status of Japanese HIV-infected patients with coagulation disorders: coinfection with both HIV and HCV
30. Successful living-related kidney transplantation in a boy with inherited dysfibrinogenemia
31. Consensus Guideline for Diagnosis and Treatment of Childhood Idiopathic Thrombocytopenic Purpura
32. Glucocorticoid Directly Enhances mRNA Levels of Endogenous Coagulation Factor VIII in Human Liver Sinusoidal Endothelial Cells
33. Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A
34. Protein C deficiency as the major cause of thrombophilias in childhood
35. REEVALUATION OF ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) REAGENTS IN JAPAN: 230
36. INF2 mutations in Charcot-Marie-Tooth disease complicated with focal segmental glomerulosclerosis
37. A New Glucose-6-Phosphate Dehydrogenase Variant G6PD Sugao (826C→T) Exhibiting Chronic Hemolytic Anemia With Episodes of Hemolytic Crisis Immediately After Birth
38. Prophylaxis Using a Mixture of Plasma-Derived Activated Factor VII and Factor X (pdFVIIa/FX) in a Patient with Hemophilia B Complicated by Inhibitors and Allergy to Factor IX Concentrates: A Case Report
39. Long-Term Safety and Efficacy of Nonacog Beta Pegol (N9-GP) Administered for at Least 5 Years in Previously Treated Children with Hemophilia B
40. Erratum to: A cohort study of the usefulness of primary prophylaxis in patients with severe haemophilia A
41. Successful treatment with vincristine of an infant with intractable Kasabach–Merritt syndrome
42. The Number of People in Japan with Coagulation Disorders: 2001 Update
43. Spontaneous platelet aggregation in Kawasaki disease using the particle counting method
44. Spectrum of F8 Genotype and Genetic Impact on Inhibitor Development in Patients with Hemophilia A from Multicenter Cohort Studies (J-HIS) in Japan.
45. Prophylaxis Using a Mixture of Plasma-Derived Activated Factor VII and Factor X (pdFVIIa/FX) in a Patient with Hemophilia B Complicated by Inhibitors and Allergy to Factor IX Concentrates: A Case Report.
46. A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors
47. Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B
48. Mother-to-Child Transmission of Hepatitis G Virus
49. Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan
50. Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.